Resumen
Este artículo es de singular importancia para todos nuestros visitantes de ambos sexos — pero, especialmente para mujeres de todas las edades — porque describe en detalle algunos de los subterfugios y métodos evasivos que utilizan las compañías que mercadean las medicinas — en connivencia con médicos poco éticos, como los que Freddy Aguasvivas describe en su libro "Todas las posibilidades" — con que, a veces, nos causan daños inmensurables.
La menopausia es normal y algunas compañías farmacéuticas desean que la tratemos como quieren que hagamos con la vejez: como si fueran enfermedades.
Lo que es peor, es que cuando se relaciona a los tratamientos para otras condiciones, como la obesidad, donde se captan más dólares, la situación es más crítica.
El por qué para esto es lo siguiente, si la obesidad permanece intratable y la menopausia una "enfermedad": ¿Quiénes se benefician?
Para nuestros lectores que deseen traducirlo, todo lo que tienen que hacer es poner el artículo en relieve con el cursor, copiarlo, y pegarlo en uno de los programas de traducción (como el que ofrece Google en su navegador).
Lean y se estremecerán de horror
Millions of American women in the 1990s were told they could help their bodies ward off major illness by taking menopausal hormone drugs. Some medical associations said so. Many gynecologists and physicians said so. Respected medical journals said so, too.
Along the way, television commercials positioned hormone drugs as treatments for more than hot flashes and night sweats — just two of the better-known symptoms of menopause, which is technically defined as commencing one year after a woman"s last menstrual cycle.
One commercial about estrogen loss by the drug maker Wyeth featured a character named Dr. Heartman in a white coat discussing research into connections between menopause and heart disease, Alzheimer"s disease and blindness.
"When considering menopause, consider the entire body of evidence," Dr. Heartman said. "Speak to your doctor about what you can do to help protect your health during and after menopause."
Connie Barton, then a medical office assistant in Peoria, Ill., was one woman who responded to such messages. She says she took Prempro, a hormone drug made by Wyeth, from 1997, when she was 53, until 2002, when she received a diagnosis of breast cancer. As part of her cancer treatment, she had a mastectomy to remove her left breast.
Now Ms. Barton, who said in an interview that she used Prempro in part because her doctor told her it could help prevent heart disease and dementia, is one of more than 13,000 people who have sued Wyeth over the last seven years, claiming in courts across the country that its menopause drugs caused breast cancer and other problems.
The suits also assert, based on recently unsealed court documents, that Wyeth oversold the benefits of menopausal hormones and failed to properly warn of the risks.
In October, a jury in a Pennsylvania state court awarded Ms. Barton $75 million in punitive damages from Wyeth on top of compensatory damages of $3.75 million.
The drug giant Pfizer, which absorbed Wyeth and its hormone drugs in a merger this year, says that Prempro is a safe, federally approved drug that did not cause Ms. Barton"s breast cancer. Chris Loder, a Pfizer spokesman, says Wyeth acted responsibly by including a clear warning about a breast cancer risk on Prempro labels and by updating the warning as new evidence emerged.
Mr. Loder also notes that Pfizer plans to appeal every product-liability case on menopausal drugs it loses, including Ms. Barton"s.
While Wyeth has faced periodic complaints about its blockbuster menopause drugs, the latest lawsuits have turned the company"s menopausal hormone franchise into the kind of case study dissected at Ivy League business schools. Lawyers have made some documents public in the suits, and The New York Times and the nonprofit Public Library of Science filed successful motions to unseal thousands of documents in July.
To be sure, even some doctors who think hormone therapy has risks say it is the most effective treatment for symptoms directly associated with menopause.
The documents that have surfaced in the Wyeth cases offer a rare glimpse inside the file cabinets and hard drives of a major drug company. And the cases demonstrate the importance of litigation in detailing exactly how drug makers operate their businesses, says Dr. Jerome L. Avorn, a professor of medicine at Harvard Medical School who has written about the subject in The Journal of the American Medical Association.
"The information coming out in litigation helps us understand how a belief in a "protective benefit" of estrogens on the heart was able to spread like wildfire through the medical community," says Dr. Avorn, who is not involved in the Wyeth litigation.
| Página siguiente |